{
  "id": "640dde93201352f04a000029",
  "type": "summary",
  "question": "What is the difference between PD-1 and PD-L1?",
  "ideal_answer": "PD-1 and PD-L1 inhibitors act to inhibit the association of the programmed death-ligand 1 (PD-L1) with its receptor, programmed cell death protein 1 (PD-1). PD-L1 is the receptor that binds to the PD-L1 protein",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/16606670",
    "http://www.ncbi.nlm.nih.gov/pubmed/20587542",
    "http://www.ncbi.nlm.nih.gov/pubmed/30851544",
    "http://www.ncbi.nlm.nih.gov/pubmed/35668012",
    "http://www.ncbi.nlm.nih.gov/pubmed/21118528",
    "http://www.ncbi.nlm.nih.gov/pubmed/21097698",
    "http://www.ncbi.nlm.nih.gov/pubmed/24031027",
    "http://www.ncbi.nlm.nih.gov/pubmed/31436392",
    "http://www.ncbi.nlm.nih.gov/pubmed/12697896",
    "http://www.ncbi.nlm.nih.gov/pubmed/30547271",
    "http://www.ncbi.nlm.nih.gov/pubmed/27903604",
    "http://www.ncbi.nlm.nih.gov/pubmed/31876895",
    "http://www.ncbi.nlm.nih.gov/pubmed/30519815",
    "http://www.ncbi.nlm.nih.gov/pubmed/17924994",
    "http://www.ncbi.nlm.nih.gov/pubmed/28960263"
  ],
  "snippets": [
    {
      "text": "To compare the real-world safety profile of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors between younger and older patients",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35668012",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Programmed Cell Death Receptor (PD-1) and its Ligand (PD-L1) pathway inhibitor therapy has been explored in the field of oncology treatment mainly for solid tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30851544",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Inhibitors of programmed cell death-1 (PD-1) and its ligand (PD-L1) have been increasingly used in head and neck cancer therapy and reported to improve the outcomes with an acceptable safety profile.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31436392",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Engagement of programmed death-1 (PD-1) with its two ligands [programmed death ligand-1 (PD-L1) and PD-L2] has been associated with the suppression of tumor-reactive T cells; however, the underlying mechanism for this T-cell dysfunction is not clear.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24031027",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PD-1 interacts with two ligands, PD-L1 and PD-L2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20587542",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) is used to select patients and analyze responses to anti-PD-1/L1 antibodies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27903604",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PD-1 has two ligands: PD-1 ligand 1 (PD-L1), which is expressed broadly on hematopoietic and parenchymal cells, including pancreatic islet cells; and PD-L2, which is restricted to macrophages and dendritic cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16606670",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Monoclonal antibodies against programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) are effective therapies in patients with non-small cell lung can",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28960263",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PD-L1 and PD-L2 are ligands for PD-1, a costimulatory molecule that plays an inhibitory role in regulating T cell activation in the periphery.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12697896",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PD-1 has two ligands: PD-L1, expressed on hematopoietic and nonhematopoietic cells, and PD-L2, limited to DCs and macrophages.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21097698",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Programmed death-1 (PD-1) is an immune checkpoint that is able to inhibit the immune system by binding to its ligand programmed death-ligand 1 (PD-L1).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30547271",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Finally, we could demonstrate that PD-L1 and PD-L2 competed for PD-1 binding and conversely, an antagonist PD-1 mAb blocked both PD-L1 and PD-L2 binding to PD-1 and strongly enhanced T-cell proliferation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20587542",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ast cancer. Programmed death-1 (PD-1) and its ligand, programmed death-ligand 1\u00a0(PD-L1), seem to have prognostic and predictive values in a variety of cancers, including female br",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30519815",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Importance: Immune checkpoint inhibitors of programmed cell death 1 (PD-1) and its ligand (PD-L1) have led to a paradigm shift in cance",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31876895",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "osuppression. Programmed death-1 (PD1) and its ligand programmed death ligand-1 (PD-L1) exert inhibitory function by regulating the balance among T cell activation, tolerance, and im",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21118528",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PD-1 has two ligands PD-L1 and PD-L2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17924994",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}